National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 62 of 66
Interleukin-12 in Treating Patients With Advanced Cancer
NCT00003330
Genetic Susceptibility to Oncogenic Viruses
NCT00341484
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
NCT00003368
Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy
NCT00019357
Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR
NCT00001698
A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers
NCT00001699
Gene Therapy in Treating Patients With Advanced Bladder Cancer
NCT00003167
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
NCT00003256
Bryostatin and Vincristine in B-Cell Malignancies
NCT00003166
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
NCT00019435
Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers
NCT00003249
Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma
NCT00341952
Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical Trials
NCT00001695
A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor
NCT00001696
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00019461
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
NCT00001686
Continuation of Follow-up of DES-Exposed Cohorts
NCT00340600
EF5 in Treating Patients With Solid Tumors
NCT00003282
Fenretinide in Treating Children With Solid Tumors
NCT00003191
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
NCT00001693
Lobradimil and Carboplatin in Treating Children With Brain Tumors
NCT00019422
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
NCT00003204
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
NCT00019396
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003210
Gene Therapy in Treating Patients With Cancer of The Liver
NCT00003147
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT00003190
A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia
NCT00001689
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
NCT00019383
A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine
NCT00001688
Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer
NCT00026897
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
NCT00001685
A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations
NCT00001681
A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
NCT00001680
Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer
NCT00004032
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
NCT00001683
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
NCT00019331
Penclomedine in Treating Patients With Solid Tumors or Lymphoma
NCT00002946
Cancer Risk in X-Ray Technologists: Second Survey
NCT00410475
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
NCT00001587
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
NCT00001586
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
NCT00003039
Depsipeptide in Treating Patients With Solid Tumors
NCT00019318
Flavopiridol in Treating Patients With Refractory Cancer
NCT00019344
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
NCT00001576
Determination of HIV-1 Production by the Prostate
NCT00001584
Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System
NCT00026871
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
NCT00001582
506U78 in Treating Patients With Refractory Hematologic Cancer
NCT00002970
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
NCT00001577
A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors
NCT00001579
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.